The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PGNX Detailed Price Forecast - CNN Money||View PGNX Detailed Summary - Google Finance|
|View PGNX Detailed Summary - Yahoo! Finance||View PGNX Stock Research & Analysis - Zacks.com|
|View PGNX Trends & Analysis - Trade-Ideas||View PGNX Major Holders - Barrons|
|View PGNX Call Transcripts - NASDAQ||View PGNX Breaking News & Analysis - Seeking Alpha|
|View PGNX Annual Report - CompanySpotlight.com||View PGNX OTC Short Report - OTCShortReport.com|
|View PGNX Fundamentals - TradeKing||View PGNX SEC Filings - Bar Chart|
|View Historical Prices for PGNX - The WSJ||View Performance/Total Return for PGNX - Morningstar|
|View the Analyst Estimates for PGNX - MarketWatch||View the Earnings History for PGNX - CNBC|
|View the PGNX Earnings - StockMarketWatch||View PGNX Buy or Sell Recommendations - MacroAxis|
|View the PGNX Bullish Patterns - American Bulls||View PGNX Short Pain Metrics - ShortPainBot.com|
|View PGNX Stock Mentions - StockTwits||View PGNX Stock Mentions - PennyStockTweets|
|View PGNX Stock Mentions - Twitter||View PGNX Investment Forum News - Investor Hub|
|View PGNX Stock Mentions - Yahoo! Message Board||View PGNX Stock Mentions - Seeking Alpha|
|View Insider Transactions for PGNX - SECform4.com||View Insider Transactions for PGNX - Insider Cow|
|View PGNX Major Holdings Summary - CNBC||View Insider Disclosure for PGNX - OTC Markets|
|View Insider Transactions for PGNX - Yahoo! Finance||View Institutional Holdings for PGNX - NASDAQ|
|View PGNX Stock Insight & Charts - FinViz.com||View PGNX Investment Charts - StockCharts.com|
|View PGNX Stock Overview & Charts - BarChart||View PGNX User Generated Charts - Trading View|
Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth
Posted on Thursday October 18, 2018
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Posted on Friday October 12, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
Posted on Thursday October 11, 2018
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase 2 clinical study. The multicenter, randomized, controlled trial will evaluate the efficacy and safety of 1095 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who are PSMA-avid, chemotherapy naïve, and progressed on abiraterone.
Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine
Posted on Tuesday October 09, 2018
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been published in The Journal of Nuclear Medicine. The study entitled, “Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma,” reports the complete results of the pivotal study of AZEDRA. This trial was the largest multicenter, prospective trial to evaluate the safety and efficacy of any therapy in patients with pheochromocytoma and paraganglioma and formed the basis of AZEDRA’s approval by the U.S. Food and Drug Administration (FDA) in July 2018.